Global Complement Deficiency Tests Market Size By Type (Serological And Immunological Assay, Molecular Diagnostic Tests), By Application (Hospitals, Diagnostic Laboratories), By Region, And Segment Fo...

The Global Complement Deficiency Tests Market was valued at USD 512.4 million in 2023 and is projected to surpass USD 947.3 million by 2031, growing at a CAGR of 8.0% during the forecast period of 2023–2031. The increasing incidence of autoimmune and infectious diseases, rising awareness about complement system disorders, and technological advancements in immunological diagnostics are key factors propelling the growth of this market. Complement deficiency tests play a crucial role in diagnosing rare immunodeficiencies and monitoring complement-mediated diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and hereditary angioedema.

Drivers:

Rising Prevalence of Autoimmune Disorders:

With the global burden of autoimmune diseases on the rise, there is a growing need for early and accurate diagnostic tools. Complement deficiency tests help clinicians detect abnormalities in the complement system, which is often implicated in diseases such as SLE and vasculitis.

Technological Advancements in Diagnostic Testing:

Innovations in diagnostic platforms—such as multiplex assays, enzyme immunoassays, and next-generation sequencing (NGS)—have improved the accuracy, speed, and cost-efficiency of complement testing, encouraging their broader adoption.

Growing Awareness and Screening Initiatives:

Increased awareness of primary immunodeficiency diseases (PIDs) and the introduction of newborn screening programs in several countries are supporting early diagnosis of complement deficiencies, which in turn is fueling market demand.

Restraints:

High Cost of Advanced Diagnostic Tests:

While newer testing platforms offer better accuracy and turnaround times, they are often expensive and may not be covered by insurance in certain regions. This limits accessibility, particularly in low- and middle-income countries.

Limited Awareness in Emerging Economies:

In developing regions, limited healthcare infrastructure and a lack of awareness about complement system disorders pose significant challenges to market growth and adoption of advanced diagnostics.

Opportunity:

Expansion in Personalized Medicine and Targeted Therapies:

As the field of precision medicine advances, complement testing is becoming an integral part of patient stratification and treatment optimization. This trend presents lucrative opportunities for market players to integrate complement diagnostics into therapeutic pathways.

Development of Point-of-Care Complement Testing Kits:

The rising demand for rapid, on-site testing solutions is prompting R&D in point-of-care (POC) complement deficiency kits. These innovations are expected to improve access to diagnostic testing in remote and underserved areas.

Market by System Type Insights:

The C3 and C4 component testing segment accounted for the largest market share in 2023. These components are routinely tested as biomarkers in various autoimmune and infectious diseases. The segment benefits from wide clinical acceptance and reimbursement support in several developed healthcare systems. Meanwhile, total complement activity (CH50 and AH50) assays are gaining traction due to their value in comprehensive functional analysis of the complement system.

Market by End-Use Insights:

Hospitals and diagnostic laboratories dominated the market in 2023, collectively accounting for over 70% of the market share. The centralized nature of these facilities allows for the deployment of complex diagnostic platforms and access to specialized immunologists. Research institutes are also emerging as a growing segment due to increasing academic and clinical research on immunodeficiencies and complement-targeted therapeutics.

Market by Regional Insights:

North America led the global market in 2023, supported by robust healthcare infrastructure, a high prevalence of autoimmune diseases, and widespread use of advanced diagnostics. Europe followed closely due to strong public health initiatives and insurance coverage. However, the Asia-Pacific region is expected to register the fastest CAGR during the forecast period, driven by growing healthcare investment, increased awareness, and rising disease burden in countries like China, India, and South Korea.

Competitive Scenario:

Key players in the global complement deficiency tests market include Thermo Fisher Scientific Inc., Siemens Healthineers, Abcam plc, Bio-Rad Laboratories Inc., QuidelOrtho Corporation, Beckman Coulter Inc., Becton, Dickinson and Company, Agilent Technologies, Euroimmun AG, and Randox Laboratories. These companies are investing in product innovation, automated testing platforms, and strategic collaborations.

In 2023, Thermo Fisher Scientific expanded its diagnostic product line with a fully automated complement system analyzer targeting mid-sized laboratories.

In 2024, Bio-Rad launched a multiplex immunoassay for complement profiling aimed at improving autoimmune disease diagnostics.

In 2025, QuidelOrtho Corporation collaborated with a global research institute to develop next-generation complement biomarkers for early detection of rare immunodeficiencies.

Scope of Work – Global Complement Deficiency Tests Market

Report Metric Details

Market Size (2023) USD 512.4 million

Projected Market Size (2031) USD 947.3 million

CAGR (2023–2031) 8.0%

Market Segments By System Type (C3, C4, CH50, AH50), By End-Use (Hospitals, Labs, Research Institutes)

Growth Drivers Rising prevalence of autoimmune diseases, technological advancements in diagnostics

Opportunities Point-of-care testing development, expansion in personalized medicine

Key Market Developments:

2023: Thermo Fisher Scientific launched a mid-throughput analyzer with AI-based result interpretation for complement component testing.

2024: Siemens Healthineers partnered with a European university hospital to enhance CH50 assay automation.

2025: Abcam introduced a comprehensive complement biomarker panel for research and clinical trials in rare disease settings.

FAQs:

1) What is the current market size of the Global Complement Deficiency Tests Market?

The market size was valued at USD 512.4 million in 2023.

2) What is the major growth driver of the Global Complement Deficiency Tests Market?

The major driver is the rising prevalence of autoimmune and immunodeficiency diseases globally.

3) Which is the largest region during the forecast period in the Global Complement Deficiency Tests Market?

North America held the largest market share in 2023, with Asia-Pacific expected to grow at the fastest rate.

4) Which segment accounted for the largest market share in Global Complement Deficiency Tests Market?

The C3 and C4 component testing segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Complement Deficiency Tests Market?

Key players include Thermo Fisher Scientific, Siemens Healthineers, Abcam plc, Bio-Rad Laboratories, QuidelOrtho Corporation, and others.